JWZ137
2021-05-11
[微笑]
[微笑]
Novavax Reports Q1 Loss, Tops Revenue Estimates<blockquote>Novavax报告第一季度亏损，收入超出预期</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":199126026,"tweetId":"199126026","gmtCreate":1620692111365,"gmtModify":1634197130389,"author":{"id":3575067142498671,"idStr":"3575067142498671","authorId":3575067142498671,"authorIdStr":"3575067142498671","name":"JWZ137","avatar":"https://static.tigerbbs.com/842968796125e5a418b21a3b4ab603ef","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑] </span><span>[微笑] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑] </span><span>[微笑] </span></p></body></html>","text":"[微笑] [微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/199126026","repostId":2134659571,"repostType":4,"repost":{"id":"2134659571","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620683709,"share":"https://www.laohu8.com/m/news/2134659571?lang=zh_CN&edition=full","pubTime":"2021-05-11 05:55","market":"us","language":"en","title":"Novavax Reports Q1 Loss, Tops Revenue Estimates<blockquote>Novavax报告第一季度亏损，收入超出预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2134659571","media":"Tiger Newspress","summary":"Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate","content":"<p>Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.</p><p><blockquote>Novavax(NVAX)公布的季度亏损为每股3.05美元，而Zacks一致估计为亏损2.65美元。相比之下，一年前每股亏损0.58美元。这些数字就非经常性项目进行了调整。</blockquote></p><p>This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.</p><p><blockquote>本季度报告的盈利意外为-15.09%。一个季度前，人们预计这家疫苗制造商每股亏损1.53美元，而实际亏损为2.70美元，令人惊讶的是-76.47%。</blockquote></p><p>Over the last four quarters, the company has surpassed consensus EPS estimates just once.</p><p><blockquote>在过去四个季度中，该公司仅一次超出了普遍的每股收益预期。</blockquote></p><p>Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.</p><p><blockquote>Novavax属于Zacks医疗-生物医学和遗传学行业，截至2021年3月的季度收入为4.4723亿美元，超过Zacks共识预期53.23%。相比之下，去年同期的收入为338万美元。过去四个季度，该公司的收入两次超过市场普遍预期。</blockquote></p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p><blockquote>基于最近发布的数据和未来盈利预期，该股近期价格变动的可持续性将主要取决于管理层对盈利看涨期权的评论。</blockquote></p><p>Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.</p><p><blockquote>自今年年初以来，Novavax股价上涨了约57.8%，而标普500的涨幅为12.7%。</blockquote></p><p>Novavax shares fell more than 12% in after hour trading.<img src=\"https://static.tigerbbs.com/eac077132362fe2bc181215b07e0d9ac\" tg-width=\"1299\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><blockquote>Novavax股价在盘后交易中下跌超过12%。</blockquote></p><p><b>What's Next for Novavax?</b></p><p><blockquote><b>Novavax的下一步是什么？</b></blockquote></p><p>While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p><blockquote>尽管Novavax今年迄今为止的表现优于市场，但投资者想到的问题是：该股的下一步走势是什么？</blockquote></p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p><blockquote>这个关键问题没有简单的答案，但是<a href=\"https://laohu8.com/S/AONE\">一</a>可以帮助投资者解决这个问题的可靠指标是该公司的盈利前景。这不仅包括当前对未来几个季度的普遍盈利预期，还包括这些预期最近的变化。</blockquote></p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p><blockquote>实证研究表明，近期股票走势与盈利预测修正趋势之间存在很强的相关性。投资者可以自己跟踪此类修正，也可以依靠Zacks Rank等久经考验的评级工具，该工具在利用盈利预测修正的力量方面拥有令人印象深刻的记录。</blockquote></p><p>Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>在本次财报发布之前，Novavax的预估修正趋势好坏参半。虽然在该公司刚刚发布的收益报告后，估计修正的幅度和方向可能会发生变化，但目前的状态意味着该股的咤克斯排名第三（持有）。因此，预计该股在不久的将来将表现与市场一致。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.</p><p><blockquote>看看未来几天对未来几个季度和本财年的预测如何变化将会很有趣。目前普遍的每股收益预期为2.49美元，下一季度营收为8.1973亿美元，本财年营收为40.7亿美元，每股收益为25.35美元。</blockquote></p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p><p><blockquote>投资者应该注意这样一个事实，即该行业的前景也会对股票的表现产生重大影响。就Zacks行业排名而言，医疗-生物医学和遗传学目前在250多个Zacks行业中排名垫底14%。我们的研究表明，Zacks排名前50%的行业的表现优于后50%的行业2比1以上。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Reports Q1 Loss, Tops Revenue Estimates<blockquote>Novavax报告第一季度亏损，收入超出预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Reports Q1 Loss, Tops Revenue Estimates<blockquote>Novavax报告第一季度亏损，收入超出预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-05-11 05:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.</p><p><blockquote>Novavax(NVAX)公布的季度亏损为每股3.05美元，而Zacks一致估计为亏损2.65美元。相比之下，一年前每股亏损0.58美元。这些数字就非经常性项目进行了调整。</blockquote></p><p>This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.</p><p><blockquote>本季度报告的盈利意外为-15.09%。一个季度前，人们预计这家疫苗制造商每股亏损1.53美元，而实际亏损为2.70美元，令人惊讶的是-76.47%。</blockquote></p><p>Over the last four quarters, the company has surpassed consensus EPS estimates just once.</p><p><blockquote>在过去四个季度中，该公司仅一次超出了普遍的每股收益预期。</blockquote></p><p>Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.</p><p><blockquote>Novavax属于Zacks医疗-生物医学和遗传学行业，截至2021年3月的季度收入为4.4723亿美元，超过Zacks共识预期53.23%。相比之下，去年同期的收入为338万美元。过去四个季度，该公司的收入两次超过市场普遍预期。</blockquote></p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p><blockquote>基于最近发布的数据和未来盈利预期，该股近期价格变动的可持续性将主要取决于管理层对盈利看涨期权的评论。</blockquote></p><p>Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.</p><p><blockquote>自今年年初以来，Novavax股价上涨了约57.8%，而标普500的涨幅为12.7%。</blockquote></p><p>Novavax shares fell more than 12% in after hour trading.<img src=\"https://static.tigerbbs.com/eac077132362fe2bc181215b07e0d9ac\" tg-width=\"1299\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><blockquote>Novavax股价在盘后交易中下跌超过12%。</blockquote></p><p><b>What's Next for Novavax?</b></p><p><blockquote><b>Novavax的下一步是什么？</b></blockquote></p><p>While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p><blockquote>尽管Novavax今年迄今为止的表现优于市场，但投资者想到的问题是：该股的下一步走势是什么？</blockquote></p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p><blockquote>这个关键问题没有简单的答案，但是<a href=\"https://laohu8.com/S/AONE\">一</a>可以帮助投资者解决这个问题的可靠指标是该公司的盈利前景。这不仅包括当前对未来几个季度的普遍盈利预期，还包括这些预期最近的变化。</blockquote></p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p><blockquote>实证研究表明，近期股票走势与盈利预测修正趋势之间存在很强的相关性。投资者可以自己跟踪此类修正，也可以依靠Zacks Rank等久经考验的评级工具，该工具在利用盈利预测修正的力量方面拥有令人印象深刻的记录。</blockquote></p><p>Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>在本次财报发布之前，Novavax的预估修正趋势好坏参半。虽然在该公司刚刚发布的收益报告后，估计修正的幅度和方向可能会发生变化，但目前的状态意味着该股的咤克斯排名第三（持有）。因此，预计该股在不久的将来将表现与市场一致。你可以在这里看到今天咤克斯排名第一（强力买入）股票的完整列表。</blockquote></p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.</p><p><blockquote>看看未来几天对未来几个季度和本财年的预测如何变化将会很有趣。目前普遍的每股收益预期为2.49美元，下一季度营收为8.1973亿美元，本财年营收为40.7亿美元，每股收益为25.35美元。</blockquote></p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p><p><blockquote>投资者应该注意这样一个事实，即该行业的前景也会对股票的表现产生重大影响。就Zacks行业排名而言，医疗-生物医学和遗传学目前在250多个Zacks行业中排名垫底14%。我们的研究表明，Zacks排名前50%的行业的表现优于后50%的行业2比1以上。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2134659571","content_text":"Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.Novavax shares fell more than 12% in after hour trading.What's Next for Novavax?While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":604,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/199126026"}
精彩评论